Chairpersons: A. Gaudric FRANCE, A. Tufail UK, J. R. Vingerling THE NETHERLANDS
S. Schmitz-Valckenberg SWITZERLAND
Should we treat subclinical CNV discovered by OCTA?
A. Tufail UK
Is it valuable to tolerate subretinal fluid in the treatment of type 1 CNV?
J. Zarranz-Ventura SPAIN
Do you rely on OCTA to retreat CNV?
R. Silva PORTUGAL
If a PDR associated with DME is treated by anti-VEGF, is it safe to space out injections?
J. R. Vingerling THE NETHERLANDS
Do you stop anti-VEGFs in persistent RVO related CME without binocular problems?
Y. Ikuno JAPAN
Should we operate early myopic foveoschisis to avoid complications?
R. Schumann GERMANY
Can we expect visual improvement in some lamellar macular hole after surgery?
C. Boon THE NETHERLANDS
What to do in chronic CSCR when serous retinal detachment reccurs after PDT?
A. Daruich-Matet FRANCE
How to manage Coat’s disease with central macular lipid exudation?
End of sessionBack